Novartis Cosentyx (secukinumab) Receives NICE Recommendation for Patients with Plaque Psoriasis

 Novartis Cosentyx (secukinumab) Receives NICE Recommendation for Patients with Plaque Psoriasis

Shots:

  • NICE has recommended Cosentyx as a cost-effective option for the treatment of mod. to sev. PsO in patients aged 6-17 yrs. who have not responded to other forms of systemic treatment & for whom these options were contraindicated or not tolerated
  • Additionally, patients will now have access to this treatment option on the NHS. The therapy is supported through the sustained efficacy and safety data across psoriasis, PsA, and axSpA with 500,000+ patients treated globally
  • Secukinumab (SC, q4w) is the first IL-17A inhibitor to be recommended by NICE & is approved in 90+ countries including the UK, in EU, US, Japan & China

Click here to­ read full press release/ article | Ref: Novartis | Image: Reuters

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post